| Identification | Back Directory | [Name]
AVE-3085 | [CAS]
450348-85-3 | [Synonyms]
AVE-3085
1,3-Benzodioxole-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-2,2-difluoro- | [Molecular Formula]
C17H13F2NO3 | [MOL File]
450348-85-3.mol | [Molecular Weight]
317.29 |
| Chemical Properties | Back Directory | [Boiling point ]
420.3±45.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
13.90±0.20(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment. | [in vivo]
AVE3085 (10 mg/kg/day, p.o.) treatment prevents the increases in the left ventricular weight, left ventricular weight/body weight ratio, mean myocyte diameter, and the expression of the hypertrophic markers ANP and β-MHC compared to the vehicle-treated mice. AVE 3085 treatment also attenuates the collagen volume fraction levels compared to the vehicle-treated mice. In the AVE3085-treated mice, the EFs, FSs, mitral E velocity, E/A ratio and LVDds are significantly improved compared to the vehicle-treated mice. AVE 3085 treatment attenuates the increase in the expression of Smad2 mRNA. Furthermore, the levels of the eNOS protein expression are significantly up-regulated in the AVE3085 group than in the vehicle-treated AB group[1]. AVE3085 (10 mg/kg, p.o.) significantly improves ACh-induced endothelium-dependent relaxations in the aortae of SHRs, and reduces systolic blood pressure in SHRs. AVE3085 treatment for 4 weeks increases levels of p-eNOS and eNOS in SHR aortae without affecting levels of eNOS and p-eNOS in WKY aortae[3]. | [IC 50]
eNOS | [storage]
Store at -20°C | [References]
[1] Chen Y, et al. AVE 3085, a novel endothelial nitric oxide synthase enhancer, attenuates cardiac remodeling in mice through the Smad signaling pathway. Arch Biochem Biophys. 2015 Mar 15;570:8-13. DOI:10.1016/j.abb.2015.02.020
[2] Xue HM, et al. AVE3085 protects coronary endothelium from the impairment of asymmetric dimethylarginine by activation and recoupling of eNOS. Cardiovasc Drugs Ther. 2012 Oct;26(5):383-92. DOI:10.1007/s10557-012-6404-2
[3] Yang Q, et al. AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 2011 Jul;163(5):1078-85 DOI:10.1111/j.1476-5381.2011.01308.x |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|